DUBLIN–(BUSINESS WIRE)–The “Alzheimer’s Disease Drugs – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s providing.
Amid the COVID-19 disaster, the worldwide marketplace for Alzheimer’s Illness Medicine estimated at US$ 5.9 Billion within the 12 months 2020, is projected to achieve a revised dimension of US$ 9.4 Billion by 2027, rising at a CAGR of 6.8% over the evaluation interval 2020-2027.
Cholinergic, one of many segments analyzed within the report, is projected to report a 7% CAGR and attain US$ 4.1 Billion by the tip of the evaluation interval. After an early evaluation of the enterprise implications of the pandemic and its induced financial disaster, development within the Memantine phase is readjusted to a revised 7.2% CAGR for the subsequent 7-year interval.
The U.S. Market is Estimated at $1.6 Billion, Whereas China is Forecast to Develop at 10.3% CAGR
The Alzheimer’s Illness Medicine market within the U.S. is estimated at US$ 1.6 Billion within the 12 months 2020. China, the world`s second largest financial system, is forecast to achieve a projected market dimension of US$ 2 Billion by the 12 months 2027 trailing a CAGR of 10.3% over the evaluation interval 2020 to 2027. Among the many different noteworthy geographic markets are Japan and Canada, every forecast to develop at 3.7% and 6.1% respectively over the 2020-2027 interval. Inside Europe, Germany is forecast to develop at roughly 4.3% CAGR.
Mixed Medicine Section to Report 5.7% CAGR
Within the international Mixed Medicine phase, USA, Canada, Japan, China and Europe will drive the 5.2% CAGR estimated for this phase. These regional markets accounting for a mixed market dimension of US$ 1.1 Billion within the 12 months 2020 will attain a projected dimension of US$ 1.6 Billion by the shut of the evaluation interval. China will stay among the many quickest rising on this cluster of regional markets. Led by international locations akin to Australia, India, and South Korea, the market in Asia-Pacific is forecast to achieve US$ 1.3 Billion by the 12 months 2027, whereas Latin America will increase at a 6.9% CAGR by means of the evaluation interval.
Choose Rivals (Whole 43 Featured):
- Daiichi Sankyo Firm Restricted
- Eisai Co Ltd
- Eli Lilly
- H Lundbeck A/S
- Johnson & Johnson
- Merz Holding GmbH & Co KG
- Ono Pharmaceutica
Key Subjects Lined:
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impression of COVID-19 and a Looming World Recession
- World Competitor Market Shares
- Alzheimer’s Illness Medicine Competitor Market Share Situation Worldwide (in %): 2020E
- World Competitor Market Shares by Section
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
- Whole Corporations Profiled: 43
For extra details about this report go to https://www.researchandmarkets.com/r/5kaxl2